アラビドプシスのマップキナーゼ4は,全身の獲得抵抗を否定的に調節する
M Petersen1, P Brodersen, H Naested
1Institute of Molecular Biology, Copenhagen University, Oster Farimagsgade 2A, 1353 Copenhagen K, Denmark.
Cell
|February 13, 2001
まとめ
アラビドプシスの変異体mpk4は,サリチル酸 (SA) 濃度を増やすことにより,体系的獲得抵抗 (SAR) を構成的に活性化します. MPK4キナーゼの活動は,SARとジャスモニック酸に反応する遺伝子発現を抑制するために不可欠です.
科学分野:
- 植物分子生物学 植物分子生物学
- 植物免疫 植物免疫とは
- アラビドプシスの研究
背景:
- システミック・アキバッド・レジスタンス (SAR) は,重要な植物防御機構である.
- 植物免疫におけるミトゲン活性化タンパク質キナーゼ4 (MPK4) の役割は完全に理解されていません.
研究 の 目的:
- 植物防御反応の調節におけるMPK4の機能を調査する.
- 系統的獲得抵抗 (SAR) とホルモンシグナル伝達におけるMPK4の役割を決定する.
主な方法:
- アラビドプシスのトランポゾン不活性化によって生成されたmpk4変異体.
- 遺伝子発現分析のために北方とマイクロアレイのハイブリッド化を利用した.
- NahGを発現するmpk4変異体と,mpk4/npr1双変異体を分析した.
主要な成果:
- mpk4変異体は,構成的なSAR,上昇したサリチル酸 (SA) レベル,および病原体に対する強化された耐性を表しています.
- SARを抑制するにはMPK4キナーゼ活性が必要で,不活性なMPK4は変異体を補完できない.
- mpk4 の SAR は SA に依存しているが,NPR1 に依存していない.
- ジャスモネート誘発遺伝子発現 (PDF1.2,THI2.1) は,NahG.を発現するmpk4変異体で阻害されています.
結論:
- MPK4は,アラビドプシス菌における全身性獲得抵抗 (SAR) の負の調節剤として作用する.
- MPK4は,ジャスモニック酸に反応する遺伝子発現に不可欠です.
- SAシグナル伝達経路は,MPK4媒介による植物免疫の調節に不可欠である.
関連する概念動画
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...